Compare FLR & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLR | RYTM |
|---|---|---|
| Founded | 1912 | 2008 |
| Country | United States | United States |
| Employees | N/A | 414 |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 6.2B |
| IPO Year | 2006 | 2017 |
| Metric | FLR | RYTM |
|---|---|---|
| Price | $43.24 | $90.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 14 |
| Target Price | $53.50 | ★ $131.14 |
| AVG Volume (30 Days) | ★ 3.0M | 697.4K |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $15,503,000,000.00 | N/A |
| Revenue This Year | $6.56 | $55.34 |
| Revenue Next Year | $7.10 | $86.06 |
| P/E Ratio | $39.14 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $37.62 | $58.71 |
| 52 Week High | $57.50 | $122.20 |
| Indicator | FLR | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 37.85 | 51.87 |
| Support Level | $39.93 | $79.72 |
| Resistance Level | $44.78 | $92.17 |
| Average True Range (ATR) | 2.08 | 5.08 |
| MACD | -0.79 | -0.16 |
| Stochastic Oscillator | 12.64 | 54.39 |
Fluor is one of the largest global providers of engineering, procurement, construction, fabrication, operations, and maintenance services.It serves a wide range of end markets, including oil and gas, chemicals, mining, metals, and transportation. The company's business is organized into three core segments: urban solutions, mission solutions, and energy solutions. Fluor generated $15.5 billion in revenue in 2025.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.